108 trial should go much smoother than the Peri trial with the amateurs KERX.
From Ergomed's website- 100 studies, 17,000 patients, 800 locations. Compare that
to the KERX clueless
that's all we can hope for at the moment, AEZS has continually let us down, we need something positive like a hog needs slop. Anyone know the usual wait time before the FDA comes back with an approval?
under the FDA "breakthrough" designation? If not why does 5 Star Equities put out press releases teasing about the FDA "breakthrough" designation with AEZS as bait in the article. If AEZS is going to apply for the breakthrough designation why have they not informed investors. What possible drug is there to qualify? It all looks like another teaser to get financing. Who knows these guys let investors know last and we always lose on the investment. It's time for large shareholders to put pressure on the BOD to push Engel out.
Let's face it these guys are total bums losing 80% of unsuspecting investor money the last 3 years. At the same time they have doubled their own bank account (cash from stock dilution) and haven't been hurt at all. They continue to go on Ritz Carlton boon-doogles as if everything is still peach, shows lack of respect for long term investors. We can only hope to break even as they hype 108 & 130 but the lack of competent management won't change.
I thought drugs were a no go once the FDA says no mas. Is it possible for Per to still get approved in Japan?
I'd have to agree unfortunately, Engel is the worst CEO I have ever invested in. Going on 3 years waiting for the guy to deliver on anything at this point. Breakeven and get out is the plan.
When Engel speaks head for cover, the guy never delivers. If he was shooting free throws he'd be O for 20
If Engel put that much effort into bringing AEZS-130 to market maybe we wouldn't be sitting at 2 bucks near the all time low. I think he must be ordering new ink and paper for the FDA submission and the delivery truck is stuck in the Mohave Desert. Never one to pass up a boon-doggle at the Ritz Carlton our fearless leader marches on.
Why the article from Marketwire in Yahoo News? Did Aeterna Zentaris apply for this designation on one of it's drugs, if not why put the article in there. More misleading than anything or will it be a positive surprise from AEZS. Just hope to break even with these guys.
I think someone's ego was involved there. It won't be a surprise when AEZS-130 gets approved, is sure looks like a slam dunk. The unknown is AEZS-130 treating Cancer Cachexia and AEZS-108 chances of approval. I'm not sure of how to handicap the odds of their approval.
The reason I'm still holding on to this underperformer, down 80% since I bought it.
1) AEZS-130 is a slam dunk but slam dunks are only worth 2 points.
1A) AEZS-130 treating Cancer Cachexia also, now this would be a major surprise and
the potential market is very very large marge.
2) AEZS-108, almost certain it finds use as a cancer treatment, time to market is
another story, it may take too long and require another company to finish the job.
3) Perifosine in MM, this one I'm not confident on. Would be a total surprise if positive
news surfaced. Perifosine does not want to be put out to pasture, someones (inventor) ego must be involved here. Could it be the captain.
has a chance to be a blockbuster drug if approved for 3 different cancer treatments. You'll kick yourself for years and tell all friends how you once owned the stock and sold it at $3 (fool). Hopefully Aeterna Zentaris management learned it's lesson from Peri's CRC failure and they won't make the same mistake with 108.
Accumulation at it's finest, I'm becoming more confident of good news
Big money wants in and vise versa, this is starting to look better every day